ARS Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SPRY research report →
Range $15 – $15
Price Chart
About the company
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings.
- CEO
- Donn Casale
- IPO
- 2020
- Employees
- 203
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on SPRY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $297.56M
- P/E
- -1.81
- Fwd P/E
- 21.66
- PEG
- 0.02
- P/S
- 3.00
- P/B
- -30.44
- EV/EBITDA
- -2.82
- Div Yield
- 0.00%
- Gross Margin
- 73.45%
- Op Margin
- -161.50%
- Net Margin
- -163.64%
- ROE
- -453.93%
- ROIC
- -105.67%
Latest fiscal year · YoY change
- Revenue
- $84.28M-5.5%
- Gross Profit
- $63.85M-6.9%
- Op Income
- $-179,448,000
- Net Income
- $-171,298,000-2241.8%
- EPS
- $-1.74-2209.1%
- OCF Growth
- -1361.2%
- FCF Growth
- -1418.5%
- 52W High
- $13.15
- 52W Low
- $2.44
- 50D MA
- $3.94
- 200D MA
- $6.90
- Beta
- 0.88
- RSI (14)
- 37
- Avg Volume
- 1.81M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ARS Pharma said neffy kept gaining share in Q3, while the company cut spending sharply and reaffirmed a path to cash flow breakeven by year-end 2027.· November 5, 2026
- U.S. net product revenue was $33.4 million in Q3, and total revenue was $37.7 million versus $32.5 million a year ago.
- neffy’s U.S. market share rose above 5% from 4% in Q3 2025, helped by a 42% year-over-year increase in end-user demand.
- The commercial team is shifting to an account-based, provider-focused model; management said field-targeted share improved to 9% from 6% year over year.
- SG&A fell to $43.5 million, more than 40% below the first-half 2026 quarterly average, as TV and broad consumer advertising were cut back.
- Management reiterated cash flow breakeven by year-end 2027 and said ARS-2 interim data is expected in Q1 2027.
Q3 2026 total revenue was $37.7 million, including $33.4 million of U.S. net product revenue for neffy, $2.6 million of ex U.S. supply revenue, and $1.7 million of collaboration revenue. Total revenue was $32.5 million in Q3 2025, including $31.3 million of net product revenue. U.S. market share surpassed 5%, up from 4% in Q3 2025, and end-user demand increased 42% year over year. Total operating expenses were $71.9 million; SG&A was $43.5 million, more than 40% below the first-half 2026 quarterly average; R&D was $18.3 million, including a one-time $12.5 million upfront payment tied to an IP license agreement. Cash, cash equivalents and short-term investments were $138.4 million at quarter-end. Management reiterated that it remains on track for cash flow breakeven by year-end 2027 and said full-year 2027 financial outlook will be provided with Q4 results.
Donn Casale framed the quarter as progress against three priorities: growing neffy share, tightening spending, and advancing ARS-2. He emphasized that the company is changing long-standing prescribing habits with targeted provider execution, and said the financial reset is intended to support breakeven by year-end 2027. On the pipeline, he highlighted ARS-2 as a potential first on-demand treatment for breakthrough CSU flares and said interim Phase 2b data should come in Q1 2027.
Kathy Scott said Q3 operating spend tracked to the company’s August guidance, with total operating expenses of $71.9 million. She highlighted the SG&A reduction to $43.5 million, driven by discontinuing linear TV and reducing broad consumer advertising, and said R&D was $18.3 million, including the $12.5 million license payment and ongoing ARS-2 work. She also noted quarter-end cash of $138.4 million and said the company will continue the lower SG&A run rate through 2027 while targeting cash flow breakeven by end-2027.
Analysts focused on the cadence of the commercial reset, payer coverage, gross-to-net, the share/revenue mix, and the license agreement. Management said some operating changes, including a new campaign, will roll out in early 2027, but that the team is already aligned around the new strategy. On payer access, they said more than 80% of commercial lives are covered, with active engagement on remaining Medicaid states and commercial plans; on gross-to-net, Donn said it is around 50%, consistent with prior comments. They also explained that the revenue/share disconnect was largely due to inventory timing, and that a term-loan draw was taken because the company had access to nondilutive capital and liked the terms.
The call showed continued adoption for neffy, with market share above 5%, unique prescribers up to nearly 45,000 since launch, and field-targeted share improving to 9%. Management also appears more disciplined on spending, with SG&A down sharply and a clearer plan to support cash flow breakeven by year-end 2027.
Revenue growth did not fully match the market-share gain because management cited inventory noise, suggesting quarterly sales may be uneven. Commercial execution is still in transition, with parts of the reset not fully implemented until early 2027, and payer access still needs improvement in remaining Medicaid states and commercial plans. ARS-2 remains pre-commercial, with interim data not expected until Q1 2027.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 65.6%
- Shares Outstanding
- 100.53M
- Float Shares
- 65.96M
of shares held by institutions
217 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Ra Capital Management, L.P. | 10.86M | 0 |
| Rubric Capital Management LP | 8.54M | ▲ 540.86K |
| Orbimed Advisors LLC | 8.29M | 0 |
| Deerfield Management Company, L.P. | 7.50M | 0 |
| Blackrock, Inc. | 5.58M | ▲ 270.51K |
| Sr One Capital Management, LP | 4.01M | 0 |
| State Street Corp | 3.69M | ▼ 42.04K |
| Ubs Group AG | 3.66M | ▲ 1.73M |
| Vanguard Group Inc | 3.51M | ▲ 8.87K |
| Tyro Capital Management LLC | 3.20M | ▼ 1.26M |
| Vanguard Capital Management LLC | 2.50M | ▼ 51.63K |
| Millennium Management LLC | 2.40M | ▼ 3.58M |
Held by 187 ETFs
Biggest fund positions in SPRY by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 2, 26 | Slebir John L | other | 1,199,482 |
| Oct 26, 26 | Slebir John L | other | 0 |
| Oct 1, 26 | Casale Donn | other | 1,036,923 |
| Sep 1, 26 | Smith Margaret Ekins | other | 1,001,738 |
| Aug 17, 26 | Smith Margaret Ekins | other | 0 |
| Jul 1, 26 | Casale Donn | other | 898,456 |
| Jun 24, 26 | RA CAPITAL MANAGEMENT, L.P. | other | 30,000 |
| Jun 24, 26 | Dadoo Rajeev | other | 30,000 |
| Jun 24, 26 | Shah Pratik | other | 30,000 |
| Jun 24, 26 | Kelly Michael | other | 30,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our SPRY coverage
Recent articles, reports, and earnings notes.
No research on SPRY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate SPRY report →ARS Pharmaceuticals: Neffy Is Gaining Traction, But Revenue Growth Needs To Catch Up
seekingalpha.com · Nov 18
CenterBook Partners LP Buys 295,532 Shares of ARS Pharmaceuticals, Inc. $SPRY
defenseworld.net · Nov 9
ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results
benzinga.com · Nov 6
ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 6
ARS Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 5
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 5
ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling
seekingalpha.com · Nov 3
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
zacks.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.